You are here: Industry Insights > Lilly

News List

Pfizer and Lilly announce top-line results from second Phase 3 study of tanezumab in osteoarthritis pain worldpharmanews
January 30, 2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced positive top-line results from a Phase 3 study evaluating tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis (OA) pain.
CVS to cover migraine drugs from Teva, Lilly; excludes Amgen firstwordpharma
January 28, 2019
A spokesperson for CVS Health said that the company would exclusively cover new migraine drugs from Eli Lilly and Teva, as reported NASDAQ Friday.
Lilly's tarnished Lartruvo faces uncertain future after FDA red-flags new patient starts fiercepharma
January 28, 2019
That was fast. Within a week of a surprise trial failure for Eli Lilly’s soft tissue sarcoma drug Lartruvo, regulators on both sides of the Atlantic have warned doctors not to start new patients on the drug.
Lilly's tarnished Lartruvo faces uncertain future after FDA red-flags new patient starts fiercepharma
January 28, 2019
That was fast. Within a week of a surprise trial failure for Eli Lilly’s soft tissue sarcoma drug Lartruvo, regulators on both sides of the Atlantic have warned doctors not to start new patients on the drug.
Cancer drug with accelerated approval fails Phase III trial europeanpharmaceuticalreview
January 24, 2019
Results did not confirm the clinical benefit of Lartruvo in combination with doxorubicin compared to doxorubicin alone…
Lilly Reports LARTRUVO Study Did Not Meet Primary Endpoint americanpharmaceuticalreview
January 23, 2019
Eli Lilly and Company reported the results of ANNOUNCE, the Phase 3 study of LARTRUVO (olaratumab), in combination with doxorubicin in patients with advanced or metastatic soft tissue sarcoma (STS)....
Lilly reports results of ANNOUNCE biospectrumasia
January 22, 2019
As ANNOUNCE did not confirm clinical benefit, Lilly is working with global regulators to determine the appropriate next steps for LARTRUVO
Lilly stops promoting cancer drug after shock trial failure pharmaphorum
January 22, 2019
Shares in Eli Lilly were down in early trading after the US drugmaker said its cancer drug Lartruvo failed to meet main survival goals in a late stage trial, prompting the company to stop promoting the already-marketed medicine.
Lilly’s Verzenios approved by NICE pharmaphorum
January 21, 2019
NICE has published draft guidance that now recommends Eli Lilly’s breast cancer drug Verzenios for use on the NHS.
Lilly’s CEO looks to M&A, but not for CAR-T or gene therapies pharmaphorum
January 15, 2019
Eli Lilly’s CEO David Ricks could sign more deals to strengthen its pipeline of cancer drugs, but is leaving gene cell-based CAR-T oncology drugs and rare disease gene therapies for others to develop......

Previous page 1 2 3 4 5 6 7 8 9 10 ... 25 26 Next page